Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy (MDC1A) Cambridge, MA (February 17, 2016): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company’s lead compound, TXA127, for the treatment of laminin-‐deficient congenital muscular dystrophy (LAMA2 MD or […]
Company Has “Green Light” to Proceed with Phase 2 Study, Planned to Initiate in Early 2016 Cambridge, MA (October 6, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation […]
TXA127 Shows Positive Activity in Fibrilin Model of Marfan Syndrome Cambridge, MA (August 18, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the use of TXA127 in […]
Results Warrant Further Research into TXA127 as a Comprehensive Single Agent Therapeutic for this Genetic Muscle Disease Cambridge, MA (August 3, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead compound, TXA127, has shown positive results in […]
Noted ALS Researcher, Robert H. Brown, Jr., Ph.D., M.D., Joins Tarix Orphan Strategic Advisory Board strong>Cambridge, MA (July 13, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead compound, TXA127, has shown positive results in the preclinical […]
Cambridge, MA (October 27, 2014): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead product candidate, TXA127, has achieved positive results in an established mouse model of Limb Girdle Muscular Dystrophy. SGCD‐/‐ (sarcoglycan delta deficient) mice demonstrate reduced […]
